Cancer immunotherapy development typically requires targeted patients to participate in clinical trials. Supported by 黄金城gcgc90官网-apple app store-黄金城集团排行榜 Specialty Health, US Oncology Research is well positioned to help organizations seeking to bring new cancer care therapies to market with clinical trial design, execution and patient identification for these investigational agents.
Innovative Research Organization
US Oncology Research is an industry-leading research organization comprised of more than 60 community-based centers across the country. The size of our network, combined with proprietary technology platforms and our innovative clinical research solutions, allows us to screen thousands of cancer patients across The US Oncology Network and expedite trial accruals.
For over 20 years, US Oncology Research has been conducting Phase I-IV clinical trials across many indications, including rare tumor types, and has played a role in the approval of 70 therapies. We have enrolled nearly 70,000 cancer patients to more than 1,700 oncology clinical trials, including more than 2,200 patients into Phase I trials.
US Oncology Research Approach
Our approach is simple—a central set of processes executed on behalf of pharmaceutical manufacturers for all participating oncology practices in each study: one budget, one contract, one institutional review board, one investigational product distribution center, one technology platform, one regulatory document collection process.
Our approach, coupled with innovative clinical trial acceleration and patient identification solutions, delivers best-in-class performance across all phases of clinical development.